Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19

Nicola Scichilone; Bruna Lo Sasso; Giulia Bivona; Luisa Agnello; Mario Barbagallo; Rosaria Vincenza Giglio; Concetta Scazzone; Caterina Maria Gambino; Marcello Ciaccio; Marcello Ciaccio; Bruna Lo Sasso; Roberto Muratore; Salvatore Milano; Roberto Muratore; Salvatore Milano

Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19

Nicola Scichilone, Bruna Lo Sasso, Giulia Bivona, Luisa Agnello, Mario Barbagallo, Rosaria Vincenza Giglio, Concetta Scazzone, Caterina Maria Gambino, Marcello Ciaccio, Marcello Ciaccio, Bruna Lo Sasso, Roberto Muratore, Salvatore Milano, Roberto Muratore, Salvatore Milano

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Objective: The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19.Methods: We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated.Results: Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3-2.95 vs median, 0.82 nmol/L; interquartile range, 0.57-1.03; P <.0001). Receiver operating characteristic curve analysis showed good accuracy of MR-proADM for predicting mortality. A MR-proADM value of 1.73 nmol/L was established as the best cutoff value, with 90% sensitivity and 95% specificity (P <.0001).Conclusion: We found that MR-proADM could represent a prognostic biomarker of COVID-19.

Original language	English
Pages (from-to)	493-498
Number of pages	6
Journal	Laboratory Medicine
Volume	52
Publication status	Published - 2021

All Science Journal Classification (ASJC) codes

Clinical Biochemistry
Biochemistry, medical

Cite this

@article{0683567af61a4621958f60284bacb920,

title = "Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19",

abstract = "Objective: The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19.Methods: We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated.Results: Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3-2.95 vs median, 0.82 nmol/L; interquartile range, 0.57-1.03; P <.0001). Receiver operating characteristic curve analysis showed good accuracy of MR-proADM for predicting mortality. A MR-proADM value of 1.73 nmol/L was established as the best cutoff value, with 90% sensitivity and 95% specificity (P <.0001).Conclusion: We found that MR-proADM could represent a prognostic biomarker of COVID-19.",

author = "Nicola Scichilone and {Lo Sasso}, Bruna and Giulia Bivona and Luisa Agnello and Mario Barbagallo and Giglio, {Rosaria Vincenza} and Concetta Scazzone and Gambino, {Caterina Maria} and Marcello Ciaccio and Marcello Ciaccio and {Lo Sasso}, Bruna and Roberto Muratore and Salvatore Milano and Roberto Muratore and Salvatore Milano",

year = "2021",

language = "English",

volume = "52",

pages = "493--498",

journal = "Laboratory Medicine",

issn = "0007-5027",

publisher = "American Society of Clinical Pathologists",

}

TY - JOUR

T1 - Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19

AU - Scichilone, Nicola

AU - Lo Sasso, Bruna

AU - Bivona, Giulia

AU - Agnello, Luisa

AU - Barbagallo, Mario

AU - Giglio, Rosaria Vincenza

AU - Scazzone, Concetta

AU - Gambino, Caterina Maria

AU - Ciaccio, Marcello

AU - Lo Sasso, Bruna

AU - Muratore, Roberto

AU - Milano, Salvatore

AU - Muratore, Roberto

AU - Milano, Salvatore

PY - 2021

Y1 - 2021

N2 - Objective: The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19.Methods: We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated.Results: Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3-2.95 vs median, 0.82 nmol/L; interquartile range, 0.57-1.03; P <.0001). Receiver operating characteristic curve analysis showed good accuracy of MR-proADM for predicting mortality. A MR-proADM value of 1.73 nmol/L was established as the best cutoff value, with 90% sensitivity and 95% specificity (P <.0001).Conclusion: We found that MR-proADM could represent a prognostic biomarker of COVID-19.

AB - Objective: The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19.Methods: We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated.Results: Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3-2.95 vs median, 0.82 nmol/L; interquartile range, 0.57-1.03; P <.0001). Receiver operating characteristic curve analysis showed good accuracy of MR-proADM for predicting mortality. A MR-proADM value of 1.73 nmol/L was established as the best cutoff value, with 90% sensitivity and 95% specificity (P <.0001).Conclusion: We found that MR-proADM could represent a prognostic biomarker of COVID-19.

UR - http://hdl.handle.net/10447/517229

UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600477/

M3 - Article

SN - 0007-5027

VL - 52

SP - 493

EP - 498

JO - Laboratory Medicine

JF - Laboratory Medicine

ER -

Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this